About: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Creator	Baric, Ralph Schäfer, Alexandra Sims, Amy Cihlar, Tomas Jordan, Robert Sheahan, Timothy Clarke, Michael Babusis, Darius Denison, Mark Feng, Joy Hogg, Alison Bauer, Laura Porter, Danielle Sellers, Scott Won, John Brown, Ariane Leist, Sarah Montgomery, Stephanie Spahn, Jamie
Source	Medline; PMC
abstract	Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease associated with more than 2468 human infections and over 851 deaths in 27 countries since 2012. There are no approved treatments for MERS-CoV infection although a combination of lopinavir, ritonavir and interferon beta (LPV/RTV-IFNb) is currently being evaluated in humans in the Kingdom of Saudi Arabia. Here, we show that remdesivir (RDV) and IFNb have superior antiviral activity to LPV and RTV in vitro. In mice, both prophylactic and therapeutic RDV improve pulmonary function and reduce lung viral loads and severe lung pathology. In contrast, prophylactic LPV/RTV-IFNb slightly reduces viral loads without impacting other disease parameters. Therapeutic LPV/RTV-IFNb improves pulmonary function but does not reduce virus replication or severe lung pathology. Thus, we provide in vivo evidence of the potential for RDV to treat MERS-CoV infections.
has issue date	2020-01-10(xsd:dateTime)
bibo:doi	10.1038/s41467-019-13940-6
bibo:pmid	31924756
has license	cc-by
sha1sum (hex)	6c3e8d0fde7d37c97f68675d4d8012c9445be551
schema:url	https://doi.org/10.1038/s41467-019-13940-6
resource representing a document's title	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
has PubMed Central identifier	PMC6954302
has PubMed identifier	31924756
schema:publication	Nat Commun
resource representing a document's body	covid:6c3e8d0fde7d37c97f68675d4d8012c9445be551#body_text
is schema:about of	named entity 'coronavirus' named entity 'pulmonary function' named entity 'lopinavir' named entity 'disease' named entity 'LPV' named entity 'Comparative' covid:arg/6c3e8d0fde7d37c97f68675d4d8012c9445be551 named entity 'infections' named entity 'respiratory disease' named entity 'LPV' named entity 'reduce' named entity 'potential' named entity 'virus' named entity 'loads' named entity 'improve' named entity 'infections' named entity 'efficacy' named entity 'virus replication' named entity 'MERS-CoV' named entity 'Middle East respiratory syndrome coronavirus' named entity 'MERS-CoV' named entity 'ritonavir' named entity 'pathology' named entity 'interferon beta' named entity 'ritonavir' named entity 'MERS-CoV' named entity 'UNC Chapel Hill' named entity 'one-way ANOVA' named entity 'Mann-Whitney' named entity 'hemorrhage' named entity 'infection' named entity 'tissue sections' named entity 'neutrophils' named entity 'pathogenesis' named entity 'equivalent dose' named entity 'PBMCs' named entity 'tissue sections' named entity 'homozygous' named entity 'air spaces' named entity 'caspase-3' named entity 'PBS' named entity 'MERS-CoV' named entity 'amino acid' named entity 'therapeutic treatment' named entity 'LPV' named entity 'DPP4' named entity 'isoflurane' named entity 'Betaseron' named entity 'viruses' named entity 'virus replication' named entity 'dialysis' named entity 'MERS-CoV' named entity 'lungs' named entity 'cell culture' named entity 'antigen' named entity 'IFNb' named entity 'ALI' named entity 'protein' named entity 'activity assays' named entity 'diffuse alveolar damage' named entity 'MERS-CoV' named entity 'gas exchange' named entity 'prophylaxis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software